Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04884659
Other study ID # JAL-1007
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 10, 2021
Est. completion date August 15, 2022

Study information

Verified date August 2022
Source Rockefeller University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

We propose to conduct a randomized 6-day isocaloric crossover feeding study in humans with prediabetes and obesity. We will study the effect of restricting the timing of caloric intake to earlier in the day (TRF) versus later in the day (usual feeding pattern, UFP) on glycemia and inflammation in an inpatient setting.


Description:

Time Restricted Feeding (TRF) is a variant of intermittent fasting that confines caloric intake to active daytime hours and involves fasting for 12 to 14 hours. Circadian misalignment caused by changes in sleeping and eating behaviors has emerged as having a detrimental impact on weight, glucose homeostasis and other cardiovascular disease-related outcomes. Feeding during active periods appears to be advantageous for weight, glucose metabolism and lipid profiles whereas feeding during the inactive period confers deleterious effects on these outcomes. Therefore, TRF shows great promise as a novel intervention for addressing obesity and related cardiovascular outcomes. Animal studies suggest that timing of feeding, including intermittent fasting or TRF, decreases inflammation and causes ketosis. Human studies that examined time restricted feeding for improvement in glycemia in as little as 4 days did not observe changes in clinical markers of inflammarion such as hsCRP. Moreover, systemic and adipose tissue inflammation as it occurs in obesity shows dynamic changes in the context of weight loss that would not be clearly apparent in a weight stable state. A potential mechanistic link between glycemic improvement and systemic inflammation would be the Receptor for Advanced Glycation End-Products (RAGE) and its soluble form (sRAGE).This form of inflammation has not been measured in reported eTRF studies and its relationship with eTRFwould bea significant contribution from the proposed study.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date August 15, 2022
Est. primary completion date August 15, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. BMI >25 kg/m2 2. If taking probiotics during screening, must agree to continue taking them at the same dosage and frequency 3. HbA1C 5.7-6.4% 4. Willing to eat only the food provided 5. Willing to follow the feeding schedule, including fasting for 14 hours/day for 7 days 6. Willing to remain on the RU inpatient 24/7 unit except for weekend passes 7. Normally sleep between the hours of 10 pm and 8 am 8. Weight stable over the last 3 months defined as no more than a 5% change Exclusion Criteria: 1. Diabetes 2. Any intermittent feeding diet within the last 2 weeks 3. HIV positive 4. Hepatitis 5. Self-reported autoimmune diseases (rheumatoid arthritis, SLE (lupus), Crohn's 6. Disease, psoriasis, etc.) 7. Current use of metformin 8. Smoked tobacco within the last 8 weeks 9. Taking any weight loss medication 10. Current use of systemic steroids 11. Allergic to adhesive tape 12. Taking clinically useful medications that contribute to significant weight loss or weight gain ie tricyclic antidepressants, some SSRIs, lithium, antipsychotics, some anticonvulsants, steroids, beta blockers, some antihistamines. 13. Currently pregnant 14. Any medical, psychological or social condition that, in the opinion of the Investigator, would jeopardize the health or well-being of the participant during any study procedures or the integrity of the data

Study Design


Intervention

Other:
Time restricted feeding arm
80% of calories consumed before 2PM, remaining 20% consumed by 4PM. Fasting for 14-16 hours
usual feeding pattern arm
All meals consumed ad lib with 50% of calories consumed after 4PM

Locations

Country Name City State
United States The Rockefeller University Hospital New York New York

Sponsors (1)

Lead Sponsor Collaborator
Rockefeller University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in glycemic variation by mean amplitude of glycemic excursion (MAGE) Day 2-Day14
Primary Change in inflammatory marker concentrations (sRAGE and hsCRP) relative to the UFP arm Day 2-Day 14
Secondary Shift from glucogenic to ketogenic metabolism in the TRF arm relative to the UFP arm by plasma metabolomics Day 2- Day 14
Secondary Change in biological indices of appetite (incretins) in TRF arm relative to UFP arm. Day 2 - Day 14
Secondary Changes in WBC transcriptomic profiles versus UFP arm between1, 7 and 14 days. Day 2 - Day 14
Secondary changes in gut mirobiome profiles in the TRFarm Day 2 - Day 14
See also
  Status Clinical Trial Phase
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2